Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 6/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | BACH1 | O14867 | 2/20 | 0.39 |
| ▸ | MAFK | O60675 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049825 | 0.83 | TRPA1 (0.50) | TRPA1NAAAMIF | |
| SCHEMBL28727094 | 0.81 | NAAA (0.48) | TRPA1NAAAMIFLMNATP53 | |
| SCHEMBL1021255 | 0.79 | — | — | |
| SCHEMBL5573221 | 0.76 | — | — | |
| SCHEMBL330924 | 0.74 | MIF (0.45) | TRPA1NAAAMIFKEAP1NFE2L2 | |
| SCHEMBL35780 | 0.74 | — | — | |
| SCHEMBL9065755 | 0.72 | — | — | |
| SCHEMBL3123999 | 0.72 | — | — | |
| SCHEMBL30102626 | 0.71 | NAAA (0.58) | TRPA1NAAAMIFKEAP1NFE2L2 | |
| SCHEMBL30102642 | 0.71 | NAAA (0.58) | TRPA1NAAAMIFKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344613-A1 | POLYTHIOUREA COMPOSITIONS AND METHODS OF USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-12-03 | — | — | US | disclosed |
| EP-1512688-A1 | Use of K-252a derivatives for the treatment of Parkinson's disease | CEPHALON, INC. (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1125938-A1 | Protein kinase inhibitors for treatment of neurological disorders | CEPHALON, INC. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1002534-A1 | Bis-Staurosporine and K-252a derivatives | CEPHALON, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| US-5756494-A | ENZYME INHIBITORS FOR NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5741808-A | ENZYME INHIBITORS FOR NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0788501-A1 | PROTEIN KINASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISORDERS | CEPHALON, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0768312-A2 | Bis-Staurosporine and K-252a derivatives | CEPHALON, INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5621101-A | PROTEIN KINASE INHIBITORS | CEPHALON, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5621100-A | PROTEIN KINASE ENZYME INHIBITORS | CEPHALON, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996013506-A1 | PROTEIN KINASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISORDERS | CEPHALON, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| US-5461146-A | Enzyme inhibitor protecting nerve cells from degeneration | CEPHALON, INC. (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0651754-A4 | BIS-STAUROSPORINE AND K-252a DERIVATIVES. | CEPHALON INC (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0651754-A1 | BIS-STAUROSPORINE AND K-252a DERIVATIVES. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002488-A1 | BIS-STAUROSPORINE AND K-252a DERIVATIVES | CEPHALON, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344613-A1 | POLYTHIOUREA COMPOSITIONS AND METHODS OF USE | PNMT, SRM, PUF60 | TRPA1 199/4885NAAA 936/4885MIF 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.